INNATEvertnoir.png
Innate Pharma présente ses résultats financiers et l'avancée de son portefeuille pour l'année 2020
18 mars 2021 02h00 HE | INNATE PHARMA
Marseille, 18 mars 2021 (GLOBE NEWSWIRE) -- Lacutamab a reçu le statut « PRIME » de l’Agence Européenne du Médicament dans le syndrome de Sézary ; le programme de développement clinique avance dans...
INNATEvertnoir.png
Innate Pharma reports Full Year 2020 financial results and business update
18 mars 2021 02h00 HE | INNATE PHARMA
Marseille, March 18, 2021 (GLOBE NEWSWIRE) -- Lacutamab received PRIME designation from the European Medicines Agency in Sezary Syndrome; clinical development program advances in mycosis fungoides...
pae.jpg
PAE Reports Fourth-Quarter and Full Year 2020 Financial Results
11 mars 2021 06h30 HE | PAE
Highlights Fourth-quarter revenue of $787.8 million; $2.7 billion for the yearFourth-quarter operating income of $20.5 million; $90.8 million for the yearFourth-quarter net loss of $6.1 million;...
LUNA_Logo4c.png
Luna Announces Fourth-Quarter and Full-Year 2020 Financial Release Date of March 11, 2021
24 févr. 2021 15h35 HE | Luna Innovations Incorporated
Roanoke, VA, Feb. 24, 2021 (GLOBE NEWSWIRE) -- ROANOKE, VA, February 24, 2021 -- Luna Innovations Incorporated (NASDAQ: LUNA) announced today it will report its fourth-quarter and full-year...
pae.jpg
PAE Announces Conference Call to Review Fourth Quarter and Fiscal Year 2020 Financial Results
18 févr. 2021 16h15 HE | PAE
FALLS CHURCH, Va., Feb. 18, 2021 (GLOBE NEWSWIRE) -- PAE (NASDAQ: PAE, PAEWW) will host a webcast and conference call at 8 a.m. ET on Thursday, March 11, 2021, to discuss the financial results for...